Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC). The Update details GeoVax's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. As well, the Update follows GeoVax's development, strategic relationships, and market opportunities. It is available for download below.
Snapshot of GeoVax
GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a uniquely-positioned clinical-stage biotechnology company developing preventative and therapeutic human vaccines against infectious diseases and cancer. The Company’s patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) technology is the foundation for producing non-infectious virus-like particles (VLPs) from the cells of the individual receiving the vaccine. Producing VLPs in a vaccinated individual mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear, while maintaining the safety characteristics of a replication-defective vector. GeoVax is focused on developing vaccines against human immunodeficiency virus (HIV), Zika virus (ZIKV), hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa), and malaria. The Company also has programs to develop a vaccine to treat chronic Hepatitis B virus (HBV) infection and to apply its MVA-VLP technology to cancer immunotherapy (immuno-oncology). GeoVax believes its expertise is complementary to a range of other human diseases for which there is an unmet medical need, and consequently, plans to expand its pipeline.
Key Points of GeoVax's Business
- GeoVax’s most advanced vaccine in the clinic, GOVX-B11, is designed to protect against the clade B subtype of the HIV virus (prevalent in the Americas, Western Europe, Japan, and Australia). This vaccine has demonstrated safety and highly reproducible immunogenicity; has successfully completed Phase 2a human clinical testing; and has entered a follow-on clinical trial with financial and operational support from the National Institutes of Health (NIH). During the quarter, GeoVax also announced results of a study demonstrating successful elicitation of a key precursor to broadly neutralize antibodies for the HIV CD4 binding site, an important step forward in HIV vaccine development. The Company plans to push this technology forward for a clade C HIV vaccine (prevalent in Africa).
- The Company’s HIV vaccine technology was developed in collaboration with researchers at Emory University, the National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC). The technology is exclusively licensed to GeoVax from Emory. GeoVax also has nonexclusive licenses to certain patents owned by the NIH used to develop the Company’s other vaccines.
- GeoVax’s novel preclinical Zika vaccine is designed to avoid a safety concerns associated with all other Zika vaccines in development. Preclinical studies in a lethal challenge model have demonstrated 100% protection. During the quarter, GeoVax announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, awarded the Company a Small Business Innovative Research (SBIR) grant of $600,000 in support of this program.
- The Company’s vaccine development activities are financially supported by the U.S. Government in the form of research grants, in-kind support in terms of animal experiments, and indirect support for human clinical trials. GeoVax’s HIV program receives substantial federal support (having received >$50 million to date from the NIH).
- By means of working with multiple collaborators on a variety of vaccine candidates, GeoVax is able to manage development risk by creating many paths on the road to selecting the best vaccine candidate.
Visit our Corporate Profile and Key Points pages
for the latest research on GeoVax Labs, Inc.